Tactile Systems Reports Strong Q1 Results, Raises Full-Year Revenue Guidance
Summary
Tactile Systems Technology reported a 23% increase in Q1 2026 revenue, significantly narrowed its net loss, and achieved positive Adjusted EBITDA, leading to an upward revision of its full-year revenue outlook.
Key Events
-
Strong Q1 Financial Performance
Total revenue increased 23% year-over-year to $75.3 million, with gross margin expanding to 76.5%.
-
Significant Profitability Improvement
Net loss narrowed to $1.8 million from $3.0 million, and Adjusted EBITDA swung to a positive $3.7 million from a loss of $0.3 million in Q1 2025.
-
Raised Full-Year Revenue Guidance
The company updated its 2026 revenue outlook to $360 million - $368 million, an increase from the prior range of $357 million - $365 million.
-
Product and Strategic Milestones
Received FDA 510(k) clearance for the next-generation AffloVest device and expanded its product portfolio through the acquisition of LymphaTech.
Analysis
The company delivered a robust first quarter, demonstrating strong operational execution and market demand for its lymphedema and airway clearance products. The significant improvement in profitability, marked by a swing to positive Adjusted EBITDA and a narrowed net loss, indicates effective cost management and leverage in its business model. The raised revenue guidance for the full year, coupled with recent FDA clearance for a new device and a strategic acquisition, suggests continued positive momentum and growth catalysts. Investors should view these results as a strong indicator of the company's improving financial health and strategic progress.
At the time of this filing, TCMD was trading at $23.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $510.3M. The 52-week trading range was $8.61 to $37.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.